Showing posts with label cell. Show all posts
Showing posts with label cell. Show all posts

Monday, 4 March 2019

Cell Culture Market to be at Forefront by 2026

New York City, 04 March 2019: According to a new research published by Polaris Market Research the global Cell Culture Market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer. Key players are aiming on expanding their cell reservoir and improving their proficiency by placing major importance on employment of highly trained specialists in order to gain a modest edge in the market. 

The European Collection of Authenticated Cell Cultures (ECACC) is attending the patent collection for Europe to carrying out research data by performing as international reservoir authority. According to VF Bioscience SAS, cell culture method is also gaining global acceptance in the field of food and beverages, a trend is projected to gain important traction in 2017. Furthermore, cell culture is also gaining prejudice as a significant factor in production of high quality plant actives.



The automation culture frameworks give exceptionally enhanced limit dealing with, higher productivity and reproducible purity levels. Steady government activities relating to expanding speculations by manufacturers and governments in biopharmaceutical assembling and high undiscovered market openings are some imperative variables representing such quick development.

The demand for cell culture has increased to an extent where traditional manual scale handling and production of the culture is unable to meet the growing requirements. This has empowered the improvement of robotized substantial scale cell culture frameworks which are equipped for delivering high throughput cell societies of high purity and in bigger amounts. The continuous advancement of cell culture systems and applications has balanced this market to expect an unfaltering and considerable development through to 2026. This increase has pushed the market significantly and the market for cell culture is estimated to reach more than USD 49 billion by 2026.

This development sought after can be credited to the evolving requirement for biopharmaceutical improvement, antibody innovative work, and protein generation; all of which depend vigorously on cytological R&D in which cell culture assumes a significant part. Increasing requirement for biopharmaceuticals is additionally expected to fuel territorial market development amid the estimate time frame.

Key Findings from the study suggest the largest share of this market in 2017 was of North America, as there are a fundamentally high number of innovative work ventures continuous in the district identified with cytological examination for proteomics, genomics, and medication and antibody advancement. Rising interest, for cell culture innovation and cell science explore in Europe has indicated noteworthy improvement and organizations have begun putting resources into creative advances and advances in cell culture applications. Asia Pacific market is anticipated to develop at lucrative pace because of changing medicinal services framework in this region that drives the demand for biotechnological items.

Cell culture sera represented more than half of revenue created in 2017 attributable to, high use rates of serum in the piece of cell societies and their generally high normal market costs. Moreover, commercialization of serum free sera is likewise anticipated that would drive showcase request in the coming years. Culture reagents including amino acids, cofactors, thrombin, and development factors, even though utilized as a part of follow amounts, represent an impressively huge offer of income attributable to their generally costly costs.

Wednesday, 6 February 2019

3D Cell Culture Market Estimated to Observe Significant Growth by 2026

New York City, 06 February 2019: The Global 3D Cell Culture Market Size is anticipated to reach over USD 2,768.8 Million by 2026 according to a new research published by Polaris Market Research.

3D cell culture is a cluster of biotic cells that are allowed to cultivate in artificial media in three dimensions. This type of cell culture used in tissue engineering and drug discovery, due to its property of providing prognostic data for in vivo tests and physiologically pertinent statistics. 3D cell cultures have a longer lifespan as well as more stability when compared to 2D cell culture system. This property makes them appropriate for long-term studies and long-term effects of the drug on cells. 3D cell culture systems are mostly grown in 3D cell colonies or bioreactors. Research studies estimated that they function similar to natural cells. due to which they have applications in oncology research.



 Rising occurrence of several types of cancer cases and the need for effective and affordable treatment are the major factor driving the growth of the 3D cell culture market. According to the World Health Organization (WHO) 2015, it is estimated approximately 8.8 million deaths due to cancer globally. In addition, development of optimized 3D assays, growing investment in healthcare, rising R&D investments, and other research associated activities are also propelling the growth of 3D cell culture market significantly. The 3D cell cultures are majorly used for testing efficacy of new drug development, which can be further used for the treatment of chronic diseases such as cancer, cardiovascular and neurological ailments. This surges implementation of the 3D cell culture by biotechnology and pharmaceutical industries, which in turn is driving the growth of 3D cell culture market.

The global 3D Cell Culture Market is segmented on the basis of products type, applications, end users, and geography. On the basis of product type, the global 3D cell culture market is segmented into Scaffold-based platforms, Bioreactors, Gels, Microchips, and Services. The scaffold based platforms are further categorized into Macro-Porous scaffolds, Microporous scaffolds, Nanoporous scaffolds, Scaffold free platforms, and Solid scaffolds. Scaffold-based cultures estimated to share the highest market in 2017. Availability of a substantial number of products based on the structure maintained 3D cell culture is attributive for the estimated share of this segment.

Based on the applications the global 3D cell culture market is segmented into Drug Discovery, Stem cell research, Cancer research, and Regenerative medicine. In 2017, Application in cancer research estimated to form the largest demand for 3D cell cultures market. On the basis of end users, the global 3D cell culture market IS segmented into Academic Institutes, Biotechnology & Pharmaceutical Companies, and Contract Research Laboratories. Biotechnology & pharmaceutical sectors dominated the market in 2017, as a significance of the developed application of technology in the drug discovery procedures in order to carry out well-organized screening and board validation.

Some major key players in global 3D Cell Culture Market include 3D Biotek, Advanced Biomatrix, Becton, and Dickinson Company (BD), corning Incorporated, Global cell solutions Inc., Thermo Fisher scientific Inc., VWR Corporation, Nanofiber solutions, Lonza Group Ltd., Synthecon incorporated, and Tecan Trading AG among others.

Wednesday, 30 January 2019

Cell Banking Outsourcing Market Key Players and Production Information analysis with Forecast

New York City, 30 January 2019: The global Cell Banking Outsourcing Market is anticipated to reach USD 4,366.9 Million by 2025 according to a new report published by Polaris Market Research. In 2017, on the basis of type, master cell banking segment capture the largest market shares in terms of revenue and hold the major share in the market. Regionally, North America accounted for the major share in the global cell banking outsourcing market.

The global Cell Banking Outsourcing market growth is primarily driven by the rising number of clinical trials which has helped in unmasking the potential of stem cells and their relative applications. Similarly, awareness for stem cell banking across multiple developing countries, and increasing governments initiatives that promote the awareness for stem cell isolation & its related benefits to influence the market growth during the forecast period. Rising research activities related to stem cell applications are expected to support the market growth during the forecast period. Furthermore, increase in the average life expectations due to advanced medical research and improved general lifestyle of the population, and straightforward regulations for the stem cell researchers is expected to create significant potential for this market in coming years. While, increasing number of adipose tissue banking has also become one of the major opportunities.



The global cell banking outsourcing market is segmented on the basis of Type, Product type, cell type and phase. On the basis of type, the market is categorized into Master Cell Banking, Viral Cell Banking, and Working Cell Banking. On the basis of product type, the market is segmented into Cord Cell Banking, Adult Stem Cell Banking, IPS Stem Cell Banking, Embryonic Stem Cell Banking, and IPS Stem Cell Banking. The cell type is further categorized into Stem Cell and Non-Stem Cell. The phase is segmented into bank storage, bank preparation and bank characterization & testing. The bank storage is further sub-segmented into Working Cell Bank Storage, Master Cell Bank Storage, and Cell Storage Stability Testing.

By geography, the global Cell Banking Outsourcing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2017, the North America cell bank outsourcing market was estimated to dominate in terms of revenue. The growth of North American market is majorly driven by the increasing number biopharmaceutical companies & manufacturers and increasing awareness for the use of stem cells as therapeutics proteins and antibiotics in this region. Asia Pacific cell banking outsourcing market is anticipated to be the fastest growing market during the forecast period owing to the increase in the life science sectors with the help of rising number of supportive governments pertaining to investment on biotechnology sector majorly in emerging economies such as China, India and Japan.

Key Findings from the study suggest various therapies available in the market are continuously concentrating on the technological advancements. Increased awareness for use of automation in pharmaceutical industry coupled with high growth in Asia Pacific region due to booming economies of India, and China are factors expected to have positive influence on the global cell banking outsourcing market over the forecast years.

The leading operating in the cell banking outsourcing market include BioReliance, Covance, GlobalStem Inc., BSL Bioservice, Cleancells, Charles River Laboratories Lonza, Toxikon Corporation, Cryobanks International India, Wuxi Apptec, Reliance Life Sciences, LifeCell International Pvt. Ltd., BioOutsource (Sartorious), CordLife, PX’Therapeutics SA, SGS Life Sciences, Texcell and Cryo-Cell International Inc among others.

Wednesday, 23 January 2019

CAR T Cell Therapy Market: Key Manufacturers, Development Trends And Competitive Analysis 2026

New York City, 23 January 2019: Global CAR T Cell Therapy Market is anticipated to reach over USD 2.99 Billion by 2025 According to a new research published by Polaris Market Research. The CAR T therapy uses the patient’s own immune system as well as develops it to target the tumor cells and execute them. This therapy is depending on the re-engineering of T-cells to make them recognize cancer cells and target such cells when they generally fail to do so. This therapy has proven very operative in patients with blood cancer who have already gone through alternative therapies such as chemotherapy.

The Choice of the Target Antigen to Define the Type of Therapy

The CD19 antigen present on the surface of the B cell has proven to be the highly effective CAR T cell therapy with approved treatment for leukemia and lymphoma where B cells have become carcinogenic. Currently, Kymriah by Novartis and Yescarta (manufactured and distributed by Kite Pharma, a subsidiary of a US-based company, Gilead Sciences) are only approved products for B Cell Acute Lymphoblastic Leukemia (ALL) and Large B-Cell lymphoma respectively. The key players in this sector are evolving new CAR-T therapies targeting different antigens for solid tumor including L1CAM, MUC16 and for blood cancers including CD123, CD22, BCMA among others.



Global Market Significance

CAR-T is a vastly revolutionary therapy which contains a distinctive business model in the pharmaceutical industry to reach the commercial stage. This therapy signifies a novel methodology with large potential in terms of manufacturing procedure and toxicity management. Leading key market players such as Novartis, Gilead, Celgene, and others are gaining full exposure to the immuno-oncology field with the ongoing merger and acquisition activities, product developments, and clinical trials to increase the importance of cellular therapy.

The Global CAR T Cell Therapy Market is segmented on the basis of the target antigen, application, and geography. On the basis of a target antigen, the global CAR T Cell Therapy Market is segmented into CD19, CD20, MESO, HER2, EGFRV III, and Others. On the basis of application, the global CAR T Cell Therapy Market is segmented into Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, and Others. The first therapy approved was observed among pediatrics and/or young adults Acute Lymphoblastic Leukemia (ALL) – an ailment with a high unmet need where CAR-T indicated high effectiveness. The therapy for Diffuse Large B-Cell Lymphoma (DLBCL) was estimated to be the largest market sharing segment followed by multiple myeloma. In addition, Chronic Lymphocytic Leukemia and follicular lymphoma are expected to be the other major market segments during the forecast period.

In terms of geography, North America region is estimated to dominate the global CAR T Cell Therapy Market. Increasing research and developments programs as well as ongoing regulatory approvals are factors attributed for the augmented market growth of CAR T cell therapy. For instance, Kymriah (a Novartis product) has cleared the USFDA approval in August 2017 for the treatment of patients suffering from acute lymphoblastic leukemia. Moreover, key players such as Novartis and Kite are the first to reach US market and are expected to focus on expansion via the number of academic centers that can provide appropriate cancer treatments in 2018.

Some major key players in global CAR T Cell Therapy Market includes Novartis International AG, Kite Pharma, Inc., Juno Therapeutics, Pfizer, Inc. Celgene Corporation, Cellectis, Sorrento Therapeutics, Bluebird bio, and Immune Therapeutics. The objective of the key market players is to deliver better chronic care administration while keeping the cost low.